Please assess the completion status of the following clinical trial:

Trial Title: Use of G-CSF for the Treatment of Unexplained Recurrent Miscarriage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* four or more previous consecutive abortion,~* failed previous treatment with intravenous immunoglobulins~* negative to all clinical investigation for recurrent miscarriage~Exclusion Criteria:~* in the last abortion a fetal karyotype showing chromosomal abnormality~* previous successful pregnancy

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Granulocyte colony stimulating factor (Type: EXPERIMENTAL): The G-CSF group of 35 women, underwent a daily sub-cutaneous administration of the filgrastim (Neupogen, Dompe', Italy), the recombinant G-CSF, at a dosage of 1 micro gram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
- placebo (saline solution) (Type: PLACEBO_COMPARATOR): The placebo group consisting of 33 subjects, was given a treatment with saline solution at the 0.2ml/day subcutaneously/, from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.

Based on this trial design, predict the completion outcome and termination type (if applicable).